Study Connect™ App Enables the Mobile Management of Randomization, Inventory Management and Unblinding in Clinical Trials
Study Connect™, a new mobile app from Merge eClinical, allow users of its eClinicalOS (eCOS) to perform a wide array of clinical trial management functions from their iOS-based mobile devices.
Seamlessly integrated with eCOS, Study Connect™enables researchers to:
· Manage randomization of subjects
· Coordinate dispensing and inventory management
· Unblind individual subjects, as circumstances warrant
· Stay connected with real-time customized notifications
· Monitor enrollment and establish milestone alerts
· Share top-level statistics for each study with key stakeholders using the study dashboard
· Expedite approval response times for critical study decisions such as patient study eligibility
· Maintain security with the ability to set customized role-based permissions for individual studies.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.